Drug Type Small molecule drug |
Synonyms GH-35, GH35 |
Target |
Action inhibitors |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | China | 27 Oct 2022 | |
Colorectal Cancer | Phase 2 | China | 27 Oct 2022 | |
KRAS mutation-related tumors | Phase 2 | China | 27 Oct 2022 | |
Non-Small Cell Lung Cancer | Phase 2 | China | 27 Oct 2022 | |
KRAS G12C mutation Solid Tumors | Phase 1 | China | - | 27 Sep 2021 |